BioSpace News Archive

Molecular Partners AG announced the completion of initial Good Manufacturing Practice manufacturing runs of its tri-specific, antiviral DARPin® candidate for COVID-19, named MP0420.

17 abstracts1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs

Evotec SE and the French-based BIOASTER Technological Research Institute announced that they have entered into a partnership to advance research for infectious diseases.

Sorrento Therapeutics, Inc. announced it has entered into an exclusive license agreement with Mayo Clinic for a potential breakthrough technology platform that is capable of generating a great diversity of stable antibody-drug-nanoparticle albumin-bound immune complexes targeting many types of human diseases including various solid and liquid tumors.

Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)

Oazis to hold a virtual demo day on September 15 showcasing groundbreaking technologies of its six portfolio companies in the fields of health, advertising, sustainability and software

Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on

- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlighting data on the investigational oral CDK4/6 inhibitor lerociclib, including updated findings from a Phase 2 trial of lerociclib in combination with fulvestrant in HR+, HER2- advanced breast cancer patients, will be featured at the ESMO Virtual 2020 Congress being held from September 19-21. G1 abstract tit

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and tolerability profile Strong efficacy profile with every two-week dosing Statistically significant improvements in markers of liver injury and key lipid parameters Conference call and webcast scheduled for 8:30 am ET (5:30 am PT) today SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc.